However, it is worth mentioning that the vaccine has caused an immune response in the human body, which does not mean that it can effectively fight HIV and prevent AIDS.
It is understood that this new method vaccine is a mosaic vaccine, which uses "mosaic technology" to combine several markers selected from specific HIV, prompting the body to make a variety of immune responses to resist the variants of HIV.
The vaccine was successful in animal experiments, in which the effective vaccination scheme reduced the infection risk of a single exposure to shiv by 94%, and 66% of monkeys were still uninfected after six exposures. Subsequently, Janssen Company began to conduct human clinical trials on volunteers from the United States, Rwanda, South Africa and Thailand.
According to the official website of Janssen Company, volunteers completed four vaccinations within 48 weeks, the first two were basic immunization, and the last two were enhanced immunization. After three injections, most volunteers developed an immune response to HIV. The results of the first human clinical trial of approach vaccine show that different chimeric vaccination schemes have good tolerance and can produce immune response against HIV in healthy adults.
Anthony Schmidt, an immunologist and director of the National Institute of Allergy and Infectious Diseases (niaid), said: "The uniqueness of HIV is that the human body cannot find a good immune response to deal with it." This is why researchers have not developed an effective AIDS vaccine after 35 years of research.
Generally speaking, a vaccine refers to injecting people with inactive viruses or bacteria. If people are attacked by these vaccines, the immune system will produce an antibody chemical. But vaccines are just empty shells of those pathogens, so we won't get sick because of them. But once you encounter this virus again in the future, you can produce antibodies quickly.